McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies.
McKesson Specialty certified to launch Revlimid
McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies. Revlimid is an oral medication for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with a missing part of chromosome 5 (known as deletion 5q MDS).
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.